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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2017, Taiwan P
NC-ND license (http://creativecommoBackground: Hypoglycemia is common in neonates and may cause adverse neurological out-
comes. Guidelines should aim to prevent repeated hypoglycemic episodes in risk groups, but
they are not usually stratified according to the severity of hypoglycemia risk, which may lead
to inappropriate and redundant interventions. We evaluated the effect of a national preven-
tion guideline stratified according to mild, moderate, and severe risks of hypoglycemia.
Methods: From national registers, a population cohort of 22,725 neonates was identified retro-
spectively before and after implementation of a national guideline. Of these, 1900 had World
Health Organization International Classification of Diseases 10 discharge diagnoses of hypogly-
cemia. Diagnoses indicating hypoglycemia risk [small/large for gestational age (SGA/LGA),
asphyxia, prematurity, maternal insulin-treated diabetes mellitus] were recorded. Neonatal
ward files were evaluated to validate hypoglycemia diagnoses. Adjusted odds ratios (aORs)
were calculated, adjusting for sex, parity, SGA, LGA, preterm birth, and asphyxia, where rele-
vant.
Results: Primiparity and male sex were associated independently with hypoglycemia diagnosis
[aORs, 1.29 (1.17e1.42) and 1.14 (1.03e1.26), respectively]. Overall incidence of hypoglyce-
mia at discharge decreased from 9.4% to 5.5% after guideline implementation [aORchange,
0.57 (0.50e0.64)]. Overall incidence of validated hypoglycemia decreased from 2.1% to 1.2%
[aOR 0.59 (0.46e0.77), p< 0.001]. By risk group, the hypoglycemia incidence decreased from
30.5% to 18.6% [aOR 0.52 (0.36e0.75)] among SGA neonates, from 25.8% to 16.4% [aOR 0.57
(0.42e0.76)] among preterm infants, and from 27.4% to 16.6% [aOR 0.63 (0.34e0.83)] among
those with asphyxia. LGA neonates showed a decreased incidence in obstetric wards only.
No significant change was observed for the diabetes group.
Conclusion: Stratification of hypoglycemia risk in a hypoglycemia prevention guideline was fol-
lowed by decreased estimated hypoglycemia incidence, but no causative conclusion could beian Andersen Children’s Hospital, Odense University Hospital and Institute of Clinically Research,
Boulevard, 5000 Odense, Denmark.
rsyd.dk (H.T. Christesen).
016.12.002
ediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
ns.org/licenses/by-nc-nd/4.0/).
Neonatal hypoglycemia 399drawn. Prospective studies with risk stratification for hypoglycemia prevention are encour-
aged.
Copyright ª 2017, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Glucose is an essential fuel for brain metabolism and,
depending on its severity and duration, hypoglycemia may
result in adverse neurological outcomes.1e4 The key to
hypoglycemia prevention is to identify neonates at risk, as
this condition may be difficult to detect clinically.1,5e8
The threshold for intervention in neonatal hypoglycemia
remains controversial.1,9 After the physiological nadir, the
mean plasma glucose level in 3e47-hour-old, healthy,
nonexclusively breastfed term neonates is 3.5e3.7 mmol/
L, with a fifth percentile of 2.2e2.3 mmol/L.10 This value is
lower in healthy, exclusively breastfed term neonates,11
but higher ketone bodies provide alternative fuel in this
group.5
In risk groups, the clinical cutoff value for treatment of
hypoglycemia is usually set around 2.5 mmol/L (45 mg/dL)
after the first hours of life. This threshold is used widely in
clinical practice, despite differences in the methods and
devices used for determination of the glucose concentra-
tion,12 and is supported by the recent guideline from The
American Academy of Pediatrics.13 Others have stated that
asymptomatic neonates at risk should not maintain glucose
levels < 2.0 mmol/L after feeding,1,14 and treatment
thresholds of 1.8 mmol/L on one occasion and 2.6 mmol/L
on multiple occasions have been proposed.15
The incidence of neonatal hypoglycemia ranges from 5%
to 15%,1,16,17 possibly reflecting differences in study pop-
ulations, preventive measures, and hypoglycemia defini-
tions and measuring techniques,18 in addition to normal
biological variation.
According to the definition of the Institute of Medicine,
clinical guidelines are “systematically developed state-
ments to assist practitioner and patient decisions about
appropriate health care for specific clinical circum-
stances”,19 and guidelines intend to improve efficiency and
quality of care and reduce inappropriate practice.20,21 Hy-
poglycemia prevention protocols should be individualized
according to risk stratification,22 and evidence-based
guidelines can improve the standard of care for neonates
with hypoglycemia.23 Although guidelines have the poten-
tial to have harmful effects as well as benefits if not eval-
uated,20,21 the consequences of guideline implementation
have not been well studied. We are not aware of any pre-
vious study evaluating the effects of the implementation of
a systematic, stratified guideline on the prevention and
treatment of neonatal hypoglycemia.
In Denmark, a national guideline for the prevention of
neonatal hypoglycemia was introduced in 2010 with the
primary aims of avoiding repeated hypoglycemic episodes
in risk groups and enhancing the quality of care. The
guideline stratified hypoglycemia risk as mild, moderate,and severe, allowing for the differentiation of preventive
actions according to severity.
In this study, we aimed to evaluate the preventive effect
of the national prevention guideline by estimating the
incidence proportions of neonatal hypoglycemia overall and
for major risk groups, before and after the guideline
implementation.2. Methods2.1. Data sources and uptake area
This retrospective, observational cohort study was based on
data from the Danish National Patient Registry (DNPR) and
the Danish Medical Birth Registry (DMBR). The DNPR con-
tains data for all hospitalized patients and newborns in
Denmark. The DMBR has more detailed information on
pregnancies and deliveries; it contains highly reliable and
valid data on 99.8% of all Danish deliveries.24 The following
data were extracted from the DNPR and DMBR for each
participant included in the study: personal identification
number, postal code, parity, gestational age (GA), sex,
birth weight, hospital/department, and all discharge di-
agnoses according to the World Health Organization Inter-
national Classification of Diseases 10 (ICD10). Additional
data were collected from the medical records of three
hospitals in the Region of Southern Denmark: Odense Uni-
versity Hospital (OUH; Department of Obstetrics and Hans
Christian Andersen Children’s Hospital) and the two adja-
cent regional hospitals Lillebaelt Hospital, Kolding (De-
partments of Obstetrics and Pediatrics) and Svendborg
Hospital (Department of Obstetrics). The OUH receives at-
risk and high-risk mothers and neonates from the Svend-
borg and Kolding uptake areas, including all mothers with
insulin-treated diabetes mellitus (mIDM). After delivery, all
mothereinfant pairs with mIDM were referred to the
neonatal ward.2.2. Guidelines
Before 2010, no uniform hypoglycemia prevention program
was established in Denmark. The national guideline was
introduced in 2010 (Table S1). In brief, infants were clas-
sified into no-, low-, moderate-, and high-risk groups at
birth, depending on the risk factors present. Prevention
measures ranged from breast contact to intravenous
glucose administration within the first 30 minutes of life. If
the first two glucose measurements were 2.5 mmol/L, no
further glucose determination was required.
400 A.H. Rasmussen et al2.3. Time periods
The preguideline period extended from August 1, 2006 to
July 31, 2008; the postguideline period extended from
January 1, 2011 to December 31, 2011, or from July 1, 2012
to December 31, 2012 (for Lillebaelt Hospital, Kolding).
Data collected between these periods were not included
due to use of pilot versions of the guideline, and the dif-
ference in the postguideline period is due to a delay in
guideline implementation at Lillebaelt Hospital, Kolding.
2.4. Risk groups
The risk groups were defined retrospectively according to
small for gestational age (SGA) or large for gestational age
(LGA) status [birth weight exceeding 2 standard de-
viations (SDs) of the reference value], prematurity (GA< 37
þ 0 weeks), asphyxia (umbilical cord pH < 7.1 and/or base
excess 10), and mIDM. Neonates with ICD10 diagnoses of
hypoglycemia (P70.0e70.9) were identified. Mothers with
mIDM attending the neonatal ward of OUH could be iden-
tified, but maternal ICD10 diabetes diagnosis codes were
generally not available in the national registries used for
the present study. Neonates with more than one hypogly-
cemia risk factor were assigned to more than one risk
group.
2.5. Blood glucose measurement
Glucose concentrations were measured using different de-
vices. In the neonatal ward of OUH, capillary blood glucose
was tested using the HemoCue 201/201þ point-of-care
testing (POCT) device until mid-April 2011, where after
the HemoCue 201 DM RT and 201 DM were used (HemoCue
denmark, A˚kandevej 21, DK-2700 Brønshøj, Denmark). The
Roche Accu-Chek Inform II system was used in the neonatal
ward of Lillebaelt Hospital, Kolding, and Radiometer ABL
800 flex analyzers were used in the obstetric departments
throughout the study period.
All HemoCue devices measured glucose concentrations
in whole blood, but the HemoCue 201 RT/201 DM device
automatically presented calculated plasma glucose values
after multiplying by 1.11.
2.6. Populations and outcome measures
We studied the incidence proportions of neonatal hypo-
glycemia in the uptake area of the hospitals for each of the
two time periods in four different patient populations,
overall and separately for risk groups (SGA, LGA, preterm,
asphyxia, and mIDM). For national registry data, the de-
nominator was the total birth count extracted from the
DNPR/DMBR for the uptake area, and the numerator (count
of neonates with hypoglycemia within the denominator
group) was based on ICD10 diagnoses of hypoglycemia
(P70.0e70.9) from the DNPR/DMBR in the neonatal period.
For obstetric ward neonatal data, the denominator con-
sisted of all neonates discharged from one of the three
obstetric wards to home, and the numerator was based on
recording of P70.0e70.9 diagnoses in the medical records.
Bedside blood glucose values were not recordedsystematically in the medical records of the obstetric de-
partments, disallowing blood-sample-based validation of
neonatal hypoglycemia diagnoses in this population. For
neonatal ward data, the denominator consisted of all ne-
onates referred to one of the two neonatal wards. The
numerator was based on recording of P70.0e70.9 diagnoses
in the medical records. For neonatal ward data on validated
hypoglycemia, the denominator was the same and the
numerator was based on recording of P70.0e70.9 diagnoses
in the medical records in cases for which data on blood
glucose level and age (in hours) at the time of blood glucose
determination were also available. These data were
analyzed to validate diagnoses of hypoglycemia. Hypogly-
cemia was defined as glucose value < 1.7 mmol/L at 0e2
hours of life and < 2.5 mmol/L after 2 hours of life.
2.7. Methodological bias (sensitivity analysis)
We reviewed a random sample of data from 400 neonates
without ICD10 hypoglycemia diagnoses in the neonatal ward
of OUH within the asphyxia and SGA hypoglycemia risk
factor groups. Hypoglycemic neonates identified by this
search, but not identified through the original registry data
search, were not included in the incidence estimates.
2.8. Statistical analysis
First, odds ratios (ORs) for hypoglycemia diagnosis with 95%
confidence intervals (CIs) were calculated based on logistic
regression models for the following risk factors: SGA, LGA,
preterm birth, asphyxia, and mIDM (where relevant), as
well as parity and sex. This analysis was conducted for the
overall patient population, across both time periods. Sec-
ond, neonatal characteristics were compared between ne-
onates with and without hypoglycemia diagnoses for each
time period using the ManneWhitney U, Student t, and c2
tests, where appropriate. Third, incidence proportions of
hypoglycemia with 95% CIs were calculated for five patient
populations (overall and separately according to risk
groups). In addition, ORs for change with 95% CIs were
calculated based on logistic regression models (univariate
and adjusted for sex, parity, SGA, LGA, preterm birth, and
asphyxia, where relevant). No adjustment for multiple
testing was performed. Data were analyzed using Stata
software (StataCorp, College Station, TX, USA).
2.9. Ethics
The Regional Ethics Committee approved the study (pro-
tocol no. S-20120119).3. Results
Overall, the study population included 22,725 neonates
(48.4% girls, 51.6% boys). The mean (SD) birth weights
were 3400 (600) g for girls and 3506 (644) g for boys. The
mean GA was 39 (2.2) weeks. Prematurity was seen in
1693 (7.4%), asphyxia in 902 (3.9%), SGA in 848 (3.7%), LGA
in 822 (3.6%), and mIDM in 245 (1.1%) neonates. In total,
Neonatal hypoglycemia 4013949 (17.3%) neonates fell into risk groups, of which 406
(10.3%) had more than one risk factor.
In univariate and adjusted analyses, SGA, LGA, preterm
birth, and asphyxia were associated strongly with increased
odds of hypoglycemia diagnosis (Table 1). Surprisingly,
primiparity status and male sex were also associated
strongly with increased adjusted ORs (aORs) for hypogly-
cemia. Neonates belonging to the risk groups defined in this
study accounted for 1289/1900 (67.8%) of all neonates with
hypoglycemia diagnoses. Accordingly, almost one-third of
neonates with such diagnoses could not be assigned to any
risk group.
The baseline characteristics of all neonates and those
with hypoglycemia, defined by discharge diagnoses, in the
two study periods are shown in Figure 1.
The estimated incidence proportion of hypoglycemia by
discharge diagnosis was 8.4% (Table 2).
National registry data showed that the incidence of hy-
poglycemia diagnoses in the SGA, LGA, preterm, and
asphyxia risk groups was 26.2% (22.7e27.0%), with no sig-
nificant difference among risk group estimates. In the
neonatal ward, the incidence of validated hypoglycemia
ranged from 5.5% to 10.5% among risk groups, but was much
higher (32.2%) in the mIDM group.
The implementation of the hypoglycemia guideline was
associated with a highly significant decrease in the inci-
dence proportion of this condition in the overall population
in all analyses (Table 2).
For neonates in the neonatal ward, the incidence of
validated hypoglycemia also decreased, from 2.1% to 1.2%
[crude OR for change, 0.55 (0.43e0.71), p< 0.001; aOR,
0.59 (0.46e0.77)].
All analyses showed decreased incidence proportions in
the SGA and preterm birth groups. For the asphyxia group, a
highly significant decrease was seen in the national registry
and in the obstetric wards, but no change was observed in
the neonatal wards. For the mIDM and LGA risk groups, no
significant change was observed in any analysis.
The change in glucose measurement technique during
the study period could theoretically have affected the
incidence of mild hypoglycemia (2.3e2.4 mmol/L) di-
agnoses within the postimplementation period. To
compensate for this bias, we conducted a subanalysis
including only OUH neonatal ward patients with validated
hypoglycemia (< 2.3 mmol/L) to April 15, 2011. ThisTable 1 Factors associated with hypoglycemia diagnosis (ICD10
Factor Crude
OR (95% CI)
p
SGA vs. AGA 4.88 (4.15e5.72) <
LGA vs. AGA 3.88 (3.27e4.61) <
Preterm 4.12 (3.54e4.54) <
Asphyxia 4.10 (3.50e4.81) <
Parity 1 vs. > 1 1.47 (1.34e1.62) <
Male vs. female 1.17 (1.06e1.28) 0.
ORs with 95% CIs based on logistic regression analysis of 22,725 neon
periods are included.
AGAZ appropriate for gestational age; CIZ confidence interval;
gestational age; ORZ odds ratio; SGAZ small for gestational age.
* OR adjusted for sex, parity, and SGA, LGA, preterm birth, and asmethodological bias correction did not change the inci-
dence estimates.
In the review of 400 neonatal ward files with ICD10 codes
for asphyxia and SGA, without discharge diagnosis codes for
hypoglycemia, we identified unreported hypoglycemia in
16.5% of neonates. Under-reporting showed a decreasing
trend between the pre- and postimplementation periods,
especially for SGA (overall, from 20% to 13%, pZ 0.18;
asphyxia, from 16% to 12%, pZ 0.42; SGA, from 24% to 14%,
pZ 0.07).
4. Discussion
In Danish neonatal departments, various initiatives to pre-
vent and treat neonatal hypoglycemia have existed for de-
cades. Until the introduction of the national guideline,
however, practices were heterogeneous, differing within as
well as between departments. The implementation of the
national guideline instituted a homogenous, consistent, and
systematic approach, and the current studywas conducted to
evaluate its effect on the risk of hypoglycemia. The retro-
spective design of our study and methodological constraints,
including the lack of a uniform blood glucose recording pro-
tocol and the quality dependence of discharge diagnoses,
except for the validation substudy that was conducted using
data from the neonatal ward, do not allow the calculation of
exact incidence estimates or drawing of definitive conclu-
sions on the causes of changes. However, the estimated
overall hypoglycemia incidence fell significantly between the
two study periods; this effect was most pronounced in the
obstetric wards, but was also seen in neonatal wards among
cases of validated hypoglycemia discharge diagnoses. No
evidence of an increase in hypoglycemia was observed after
the guideline introduction, suggesting that the uniform inci-
dence decrease was not due to methodological bias.
The overall population incidence of neonatal hypogly-
cemia, according to discharge diagnosis, was 8.4%, which
was within previously reported incidences of
5e15%.2,7,8,16,17,25,26 Our estimate had the advantage of
being based on a large population birth cohort, but the
disadvantage of being based predominantly on discharge
diagnoses and glucose measurements obtained with
different methods. Validation exercises for these diagnoses
showed both over- and under-reporting of hypoglycemia
compared with medical records reviews.discharge diagnosis).
value Adjusted*
OR (95% CI)
p
0.001 3.39 (2.86e4.03) < 0.001
0.001 4.10 (3.43e4.90) < 0.001
0.001 3.41 (3.04e3.96) < 0.001
0.001 4.20 (3.56e4.95) < 0.001
0.001 1.29 (1.17e1.42) < 0.001
001 1.14 (1.03e1.26) 0.008
ates in the national registry database are presented. Both time
ICDZ International Classification of Diseases; LGAZ large for
phyxia, where relevant.
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Figure 1 Baseline characteristics for all neonates, and neonates at risk of hypoglycemia, defined by discharge diagnosis, before
and after implementation of a national guideline for the prevention of hypoglycemia. DMZ diabetes mellitus; LGAZ large for
gestational age; SGAZ small for gestational age.
402 A.H. Rasmussen et alIn a multivariable analysis, we identified SGA, LGA,
preterm birth, and asphyxia as independent risk factors for
hypoglycemia. These risk groups, as well as the risk faced
by infants of diabetic mothers, are well known.5,7,25,27
Almost one-third of our neonates with hypoglycemia di-
agnoses were not assigned to a risk group. One explanation
for this finding could be missing discharge diagnoses of
gestational diabetes, which in the absence of hypoglycemia
could have been reported in the mothers’ hospital records
only, and hence not included in the current study. Sur-
prisingly, the analysis based on the identified risk groups
showed that primiparity and male sex were independent
risk factors for hypoglycemia. Explanatory factors may
include delayed onset of lactogenesis in breastfeeding
primipara28 and increased male representation in neonatesbelow the LGA cutoffs, but > 4000 g, above which the risk
of hypoglycemia also may be increased.29
The overall incidence of hypoglycemia according to
discharge diagnosis among the risk groups of SGA, LGA,
preterm birth, and asphyxia was 26.2%. Others have re-
ported hypoglycemia incidences among at-risk neonates of
11.7e51%.18,26,30 In the analysis restricted to neonatal ward
data for newborns with validated hypoglycemia, the inci-
dence was at the lower end of this reported range (12.4%).
The estimated incidence of hypoglycemia diagnosis fell
significantly after the implementation of the prevention
guideline. This change may be attributed to a preventive ef-
fect of the guideline, but the contribution of methodological
bias, including errors in discharge diagnoses and variations in
blood glucose measurement counts and methods, cannot be
Table 2 Incidence proportions of hypoglycemia before and after national guideline implementation, and ORs for change.
Incidence proportions (95% CI) in relation to guideline
implementation, % (range)
OR (95% CI) for change
Both periods Before After Crude OR p Adjusted* OR p
National registry
Overall 8.4 (8.0e8.8) 9.4 (9.0e9.9) 5.5 (4.9e6.1) 0.55 (0.49e0.62) < 0.001 0.57 (0.50e0.64) < 0.001
SGA 27.0 (24.0e30.1) 30.5 (26.9e34.5) 18.6 (13.9e23.9) 0.51 (0.36e0.74) < 0.001 0.52 (0.36e0.75) < 0.001
LGA 23.6 (19.9e25.7) 25.3 (19.9e26.7) 21.1 (15.8e27.3) 0.89 (0.60e1.30) 0.554 0.96 (0.65e1.41) 0.839
Preterm 23.6 (21.6e25.7) 25.8 (23.4e28.2) 16.4 (12.9e20.0) 0.56 (0.42e0.75) < 0.001 0.57 (0.42e0.76) < 0.001
Asphyxia 25.3 (22.6e28.3) 27.4 (24.2e30.8) 16.6 (11.3e23.0) 0.52 (0.34e0.81) 0.004 0.53 (0.34e0.83) 0.006
Obstetric ward neonates
Overall 5.3 (5.0e5.6) 6.1 (5.8e6.5) 3.0 (2.7e3.5) 0.48 (0.41e0.56) < 0.001 0.51 (0.43e0.59) < 0.001
SGA 13.2 (11.0e15.6) 15.0 (12.8e18.8) 9.1 (5.8e13.3) 0.56 (0.35e0.92) 0.022 0.55 (0.34e0.90) 0.018
LGA 10.3 (8.3e12.6) 11.2 (8.8e13.9) 7.7 (4.5e12.1) 0.66 (0.38e1.17) 0.156 0.66 (0.38e1.18) 0.167
Preterm 11.1 (9.6e12.7) 12.2 (10.4e14.1) 7.7 (5.3e10.7) 0.60 (0.40e0.90) 0.014 0.61 (0.48e0.78) 0.016
Asphyxia 18.2 (15.7e20.8) 20.3 (17.4e23.4) 8.9 (5.1e14.2) 0.38 (0.22e0.67) 0.001 0.37 (0.21e0.65) 0.001
Neonatal ward neonates
Overall 3.0 (2.8e3.3) 3.3 (3.0e3.6) 2.4 (2.0e2.8) 0.72 (0.60e0.86) 0.001 0.76 (0.63e0.77) 0.001
SGA 13.7 (11.5e16.3) 15.6 (0.13e0.19) 9.3 (6.2e13.8) 0.56 (0.35e0.91) 0.019 0.55 (0.28e0.87) 0.018
LGA 12.4 (10.2e14.8) 12.0 (9.6e14.8) 13.5 (9.1e18.8) 1.14 (0.71e1.80) 0.573 1.30 (0.81e2.11) 0.286
Preterm 12.5 (10.9e14.1) 13.6 (11.8e15.6) 8.7 (6.1e11.9) 0.60 (0.41e0.88) 0.010 0.59 (0.40e0.88) 0.009
Asphyxia 7.2 (5.6e9.0) 7.1 (5.3e9.1) 7.7 (4.1e12.7) 1.09 (0.58e2.10) 0.579 1.27 (0.65e2.46) 0.482
Neonatal ward, validated hypoglycemia
Overall 1.8 (1.7e2.0) 2.1 (1.9e2.3) 1.2 (0.1e0.2) 0.55 (0.43e0.71) < 0.001 0.59 (0.46e0.77) < 0.001
SGA 10.5 (8.5e12.7) 11.9 (9.4e14.8) 7.1 (4.2e11.0) 0.62 (0.31e0.93) 0.003 0.56 (0.34e0.94) 0.021
LGA 6.2 (4.6e8.1) 6.8 (5.0e9.1) 4.3 (2.0e8.0) 0.62 (0.29e1.29) 0.204 0.72 (0.33e1.55) 0.406
Preterm 7.9 (6.7e9.3) 9.4 (7.9e11.2) 2.9 (1.6e5.2) 0.29 (0.16e0.54) < 0.001 0.28 (0.15e0.52) < 0.001
Asphyxia 5.5 (4.2e7.4) 5.4 (3.9e7.4) 6.5 (3.3e11.3) 1.20 (0.61e2.40) 0.594 1.33 (0.65e2.73) 0.430
Maternal diabetes,
insulin-treated
32.2 (26.4e38.4) 34.5 (27.3e42.3) 27.5 (18.1e38.6) 1.2 (0.40e1.29) 0.270 0.83 (0.45e1.53) 0.559
Bias-corrected
hypoglycemia
1.8 (1.6e1.9) 2.1 (1.9e2.3) 1.1 (0.8e1.4) 0.44 (0.30e0.55) <0.001 0.43 (0.31e0.58) <0.001
CIZ confidence interval; LGAZ large for gestational age; ORZ odds ratio; SGAZ small for gestational age.
* Adjusted for sex, parity, SGA, LGA, preterm birth, and asphyxia, where relevant.
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404 A.H. Rasmussen et alruled out. In support of a true decrease in the incidence of
hypoglycemia, a decreased incidence was also seen in the
validation exercise. Moreover, our subanalysis of neonatal
ward cases of glucose values < 2.3 mmol/L also showed a
highly significant decrease in the incidence.
Decreases in the estimated incidence of hypoglycemia
were seen in the SGA and preterm risk groups, regardless of
data source. The decrease in preterm neonates occurred
despite a decrease in the mean GA and birth weight, which
would tend to increase the risk of hypoglycemia, among all
such neonates in the postguideline period.
For neonates with asphyxia, a decrease was seen only in
the obstetric ward, suggesting that hypoglycemia preven-
tion in the neonatal wards was effective before guideline
implementation, or that detection of hypoglycemia among
those with milder asphyxia in the obstetric ward who were
not referred to the neonatal ward was more complete after
guideline implementation.
The LGA and mIDM risk groups showed no decrease in
hypoglycemia, regardless of the data source. The un-
changed incidence in the LGA group may reflect the ease of
hypoglycemia prevention in this group by early feeding; a
prevention strategy which was carried out before guideline
implementation. For mIDM, the avoidance of hypoglycemia
in this patient group received much attention before
guideline implementation.
Ongoing controversy regarding the definition and con-
sequences of hypoglycemia, and the methodological prob-
lems associated with POCT device use, raises open
questions about the appropriateness of the prevention
strategy examined here and elsewhere. At the least, the
national prevention program introduced less-intrusive in-
terventions for low-risk neonates without increasing the
incidence of hypoglycemia in any risk group.
The strengths of our study included the examination of a
large, population-based birth cohort; the inclusion of data
from several sources; the validation of hypoglycemia di-
agnoses; and the adjustment of analyses of incidence
changes in risk groups. Limitations included the retrospec-
tive design, with the risk of inaccuracy of discharge di-
agnoses and medical records; the methodological problems
associated with glucose measurement using different POCT
devices; the noninclusion of neonates with diet-treated
maternal diabetes; and potential undiscovered reporting
bias from unidentified changes in practice.
We conclude that the introduction of a standardized,
stratified hypoglycemia prevention program was followed
by the use of a more systematic and consistent prevention
strategy for hypoglycemia. The stratification of risk as mild,
moderate, and severe, which enables the implementation
of differentiated prevention initiatives, was met not by an
increased hypoglycemia incidence, but by strong sugges-
tions of a decrease. These findings encourage the further
use of a stratified approach, which should be studied in
other settings using a prospective design.Conflicts of interest
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